Tom Marshall. Show Affiliations »
Abstract
Mesh: See more » Cost-Benefit AnalysisHumansOrphan Drug Production/economicsRare Diseases/drug therapyState Medicine
Year: 2005 PMID: 16282417 PMCID: PMC1283315 DOI: 10.1136/bmj.331.7525.1144-b
Source DB: PubMed Journal: BMJ ISSN: 0959-8138